Literature DB >> 24323591

Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future.

Ishwaria M Subbiah1, Ana Maria Gonzalez-Angulo.   

Abstract

OPINION STATEMENT: The natural history of HER2-positive breast cancer significantly changed in the past 15 years. Form being the most aggressive type of breast cancer, it became treatable with important cure rates. However, with new and successful drugs, resistance emerges. Progress in research and drug development continues to make available effective anti-HER2 therapies. Our challenge today is to use these tools correctly by looking at the data that support the indications of each compound and to continue clinical trial participation.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24323591      PMCID： PMC3933950          DOI： 10.1007/s11864-013-0262-4

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  60 in total

1.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

2.  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Authors:  M A Molina; J Codony-Servat; J Albanell; F Rojo; J Arribas; J Baselga
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

3.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Authors:  M A Cobleigh; C L Vogel; D Tripathy; N J Robert; S Scholl; L Fehrenbacher; J M Wolter; V Paton; S Shak; G Lieberman; D J Slamon
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

4.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Authors:  Gunter von Minckwitz; Andreas du Bois; Marcus Schmidt; Nicolai Maass; Tanja Cufer; Felix E de Jongh; Eduard Maartense; Christoph Zielinski; Manfred Kaufmann; Wolfgang Bauer; Klaus H Baumann; Michael R Clemens; Ralph Duerr; Christoph Uleer; Michael Andersson; Robert C Stein; Valentina Nekljudova; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

5.  Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.

Authors:  K Lindemann; J Resau; J Nährig; E Kort; B Leeser; K Annecke; A Welk; J Schäfer; G F Vande Woude; E Lengyel; N Harbeck
Journal:  Histopathology       Date:  2007-07       Impact factor: 5.087

6.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

Authors:  Andrew D Seidman; Donald Berry; Constance Cirrincione; Lyndsay Harris; Hyman Muss; P Kelly Marcom; Grandella Gipson; Harold Burstein; Diana Lake; Charles L Shapiro; Peter Ungaro; Larry Norton; Eric Winer; Clifford Hudis
Journal:  J Clin Oncol       Date:  2008-04-01       Impact factor: 44.544

7.  Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.

Authors:  David L Shattuck; Jamie K Miller; Kermit L Carraway; Colleen Sweeney
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

8.  Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Authors:  George E Peoples; Jarrod P Holmes; Matthew T Hueman; Elizabeth A Mittendorf; Asna Amin; Steven Khoo; Zia A Dehqanzada; Jennifer M Gurney; Michael M Woll; Gayle B Ryan; Catherine E Storrer; Dianna Craig; Constantin G Ioannides; Sathibalan Ponniah
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

Review 9.  HER2 therapy: molecular mechanisms of trastuzumab resistance.

Authors:  Rita Nahta; Francisco J Esteva
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

10.  FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.

Authors:  Hazem Ghebeh; Eman Barhoush; Asma Tulbah; Naser Elkum; Taher Al-Tweigeri; Said Dermime
Journal:  BMC Cancer       Date:  2008-02-23       Impact factor: 4.430
View more
  9 in total

1.  Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity.

Authors:  Tyler Risom; Xiaoyan Wang; Juan Liang; Xiaoli Zhang; Carl Pelz; Lydia G Campbell; Jenny Eng; Koei Chin; Caroline Farrington; Goutham Narla; Ellen M Langer; Xiao-Xin Sun; Yulong Su; Colin J Daniel; Mu-Shui Dai; Christiane V Löhr; Rosalie C Sears
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

Review 2.  Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention.

Authors:  Nadia F Nocera; M Catherine Lee; Lucy M De La Cruz; Cinthia Rosemblit; Brian J Czerniecki
Journal:  Front Pharmacol       Date:  2016-10-06       Impact factor: 5.810

3.  Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.

Authors:  Maria Kuznetsova; Julia Lopatnikova; Julia Khantakova; Rinat Maksyutov; Amir Maksyutov; Sergey Sennikov
Journal:  BMC Immunol       Date:  2017-06-20       Impact factor: 3.615

4.  Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.

Authors:  Masakazu Toi; Zhimin Shao; Sara Hurvitz; Ling-Ming Tseng; Qingyuan Zhang; Kunwei Shen; Donggeng Liu; Jifeng Feng; Binghe Xu; Xiaojia Wang; Keun Seok Lee; Ting Ying Ng; Antonia Ridolfi; Florence Noel-Baron; Francois Ringeisen; Zefei Jiang
Journal:  Breast Cancer Res       Date:  2017-04-11       Impact factor: 6.466

5.  Cytotoxic Activity and Memory T Cell Subset Distribution of in vitro-Stimulated CD8+ T Cells Specific for HER2/neu Epitopes.

Authors:  Maria Kuznetsova; Julia Lopatnikova; Julia Shevchenko; Alexander Silkov; Amir Maksyutov; Sergey Sennikov
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

Review 6.  Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.

Authors:  Nehad M Ayoub; Kamal M Al-Shami; Rami J Yaghan
Journal:  Breast Cancer (Dove Med Press)       Date:  2019-01-17

7.  Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors.

Authors:  Elisa I Rivas; Jenniffer Linares; Melissa Zwick; Andrea Gómez-Llonin; Marc Guiu; Anna Labernadie; Jordi Badia-Ramentol; Anna Lladó; Lídia Bardia; Iván Pérez-Núñez; Carolina Martínez-Ciarpaglini; Noelia Tarazona; Anna Sallent-Aragay; Marta Garrido; Toni Celià-Terrassa; Octavio Burgués; Roger R Gomis; Joan Albanell; Alexandre Calon
Journal:  Nat Commun       Date:  2022-09-09       Impact factor: 17.694

8.  Physical Intimacy of Breast Cancer Cells with Mesenchymal Stem Cells Elicits Trastuzumab Resistance through Src Activation.

Authors:  Amita Daverey; Allison P Drain; Srivatsan Kidambi
Journal:  Sci Rep       Date:  2015-09-08       Impact factor: 4.379

Review 9.  Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab.

Authors:  Jahnavi Gollamudi; Jenny G Parvani; William P Schiemann; Shaveta Vinayak
Journal:  Cancer Manag Res       Date:  2016-02-18       Impact factor: 3.989
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.